Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Deucravacitinib

bb1c7a18-bb63-5c9d-868f-0640e7c0289a · FDA Approved · targets TYK2

Deucravacitinib

MeasuredReference

Deucravacitinib targets C_MET, FGFR3, FGFR2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

C_METFGFR3FGFR2FGFR4FGFR1

Top hallmarks

  • tumor promoting inflammation3.2k
  • proliferation3.0k
  • evading apoptosis2.9k

Top pathways disrupted

  • pi3k akt mtor signaling6.0k
  • apoptosis5.2k
  • apical junction5.0k

Resistance landscape — Deucravacitinib

MeasuredReference

10 known oncogenic variants exist on Deucravacitinib's top targets — see detail for inhibition impact.

Open in new tab